Product
GLPG3667
2 clinical trials
2 indications
Indication
DermatomyositisIndication
Systemic Lupus ErythematosusClinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With DermatomyositisStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2025-12-01